Skip to main content
Premium Trial:

Request an Annual Quote

To Buy or Not to Buy

At Forbes's Science Business blog Matthew Herper wonders whether Amgen should acquire Human Genome Sciences. Biotech analyst Geoffrey Porges says it should, and that the price tag could be as high as $6.5 billion. Porges points out that Benlysta, Human Genome's lupus drug, is "one of the hotter biotech products" and that Amgen has more to offer Human Genome than GlaxoSmithKline, which has the rights to co-market Benlysta, does. "[Porges] argues that Amgen could do a lot more for Human Genome than Glaxo could, by immediately increasing manufacturing capacity, an existing sales force that visits the rheumatologists and dermatologists," Herper writes.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.